Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2009

View Archived Issues

Clinical development reported for SparVax, a recombinant protective antigen anthrax vaccine

AstraZeneca researchers describe new Axl and c-Met inhibitors

Recent Protia patent imparts novel antipsychotic deuterium-enriched olanzapine analogues

Solvay reports a novel sildenafil prodrug for erectile dysfunction in recent patent

ChemoCentryx discloses new chemokine CCR2 receptor antagonists for RA and other conditions

New Nav1.7 sodium channel blockers presented by AstraZeneca

Lilly patents novel farnesoid X receptor agonists for the treatment of lipoprotein disorders

Novel soluble epoxide hydrolase inhibitors disclosed by Merck & Co.

Basilea provides update on Zevtera regulatory delays

GW reports encouraging results in randomized withdrawal Sativex study

BioDiem and Nobilon commence phase I clinical trials for LAIV

Primary objective of STRIDE-PD Stalevo study was not achieved

Antibody fragment ESBA-105 enters phase IIa studies for uveitis

Camurus initiates phase I/II CAM-2038 trial for opiate addiction

CPEX initiates phase II Nasulin trial in type 2 diabetes

Xencor and CSL sign antibody optimization collaboration including access to XmAb

Opsona signs collaboration agreement with CSL in infectious diseases and oncology

Ambrx and Merck Serono sign agreement to develop and commercialize ARX-424 for MS

ImmunoCellular identifies new peptides to broaden applicability of ICT-121 cancer vaccine

Kapidex delayed-release capsules available for the treatment of GERD

Drug scaffold targeting choline-binding proteins created for pneumococcal infections

Orexin receptor-2 agonism inhibits diet-induced obesity in mice

NeuroSearch reports phase II proof-of-concept results for NS-2359 in depression

Phase III budesonide trial in children with asthma did not meet primary endpoints

Pfizer discontinues development of two phase III compounds